Comparative characteristics of neuropsychological and neurometabolic changes in patients with Alzheimer’s disease and vascular cognitive impairment

Emelin A.Y.; Odinak M.M.; Lobzin V.Y.; Kolmakova K.A.

doi:https://doi.org/10.17116/jnevro202412404217

Emelin A.Y.

Kirov Military Medical Academy

ORCID: 0000-0002-4723-802X

Odinak M.M.

Kirov Military Medical Academy

ORCID: 0000-0002-7314-7711

Lobzin V.Y.

Kirov Military Medical Academy;
Mechnikov North-Western State Medical University

SPIN RSCI: 7779-3569
Scopus AuthorID: 57203881632
ResearcherID: I-4819-2016
ORCID: 0000-0003-3109-8795

Kolmakova K.A.

Kirov Military Medical Academy

ORCID: 0000-0001-8657-1901

Comparative characteristics of neuropsychological and neurometabolic changes in patients with Alzheimer’s disease and vascular cognitive impairment

Authors:

Emelin A.Y., Odinak M.M., Lobzin V.Y., Kolmakova K.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(4‑2): 17‑24

DOI: 10.17116/jnevro202412404217

Read: 2053 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Emelin AY, Odinak MM, Lobzin VY, Kolmakova KA. Comparative characteristics of neuropsychological and neurometabolic changes in patients with Alzheimer’s disease and vascular cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(4‑2):17‑24. (In Russ.)
https://doi.org/10.17116/jnevro202412404217

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To investigate the pattern and connections of neuropsychological and metabolic indices in patients with cognitive disorders of Alzheimer’s and vascular (subcortical-cortical) types of different severity.

MATERIAL AND METHODS

A total of 177 patients were examined, including 85 patients with Alzheimer’s disease (AD) and 92 patients with vascular cognitive impairment (VCI). All patients underwent complex neuropsychological examination; ¹⁸F-FDG PET was performed in 17 patients with AD and 15 patients with VCI.

RESULTS

The greatest changes in patients with AD were noted in the mnestic sphere, and the indicators significantly differed from the results of the study of patients with VCI already at the pre-dementia stage. Neurodynamic and dysregulatory disorders prevailed in patients with VCI. Patients with AD showed bilateral symmetrical reduction of metabolic activity in the cortex of parietal and temporal lobes, often in combination with marked hypometabolism in the hippocampal region. In patients with VCI, there were areas of decreased brain tissue metabolism of different localization and size, mainly in the projection of the basal ganglia and in the prefrontal and parietal cortex, as well as in the cingulate gyrus, which indirectly confirms the mechanism of disconnection of subcortical and cortical structures. In AD, impaired metabolic activity in the hippocampal region correlated with impaired temporal and spatial orientation (ρ=–0.54, p<0.05), memory impairment (ρ=–0.71, p<0.005). Hypometabolism of the parietal lobe cortex was associated with total MMSE score (ρ=–0.8, p<0.001), 10-word test (ρ=–0.89, p<0.001 and ρ=–0.82, p<0.001), visual-spatial impairment (ρ=–0.64, p<0.01), categorical association test (ρ=–0.73, p<0.005). In patients with VCI, dysregulatory disorders correlated with hypometabolism in the thalamic projection (ρ=–0.56, p<0.05), prefrontal cortex (ρ=–0.64, p<0.05) and in the cingulate gyrus (anterior regions) (ρ=–0.53, p<0.05).

CONCLUSION

The results indicate the presence of differences in cognitive impairment and cerebral metabolism in patients with AD and VCI.

Keywords:

cognitive impairment

mild cognitive impairment

dementia

neuropsychological assessment

positron emission tomography

Alzheimer’s disease

vascular cognitive impairment

Authors:

Emelin A.Y.

Kirov Military Medical Academy

ORCID: 0000-0002-4723-802X

Odinak M.M.

Kirov Military Medical Academy

ORCID: 0000-0002-7314-7711

Lobzin V.Y.

Kirov Military Medical Academy;
Mechnikov North-Western State Medical University

SPIN RSCI: 7779-3569
Scopus AuthorID: 57203881632
ResearcherID: I-4819-2016
ORCID: 0000-0003-3109-8795

Kolmakova K.A.

Kirov Military Medical Academy

ORCID: 0000-0001-8657-1901

Received:

14.01.2024

Accepted:

26.01.2024

Close metadata

References:

Yakhno NN, Preobrazhenskaya IS, Zakharov VV, et al. Prevalence of cognitive impairments in neurological diseases: Analysis of the activities of a specialized outpatient reception office. Neurology, Neuropsychiatry, Psychosomatics. 2012;4(2):30-35. (In Russ.). https://doi.org/10.14412/2074-2711-2012-378
Luria AR. Higher cortical function. 2-e izd. M.: MGU; 1969. (In Russ.).
Emelin AYu. The possibilities of diagnosing and treating cognitive impairment at non-dementia stages. Neurology, Neuropsychiatry, Psychosomatics. 2020;12(5):78-83. (In Russ.). https://doi.org/10.14412/2074-2711-2020-5-78-83
Del Sole A, Malaspina S, Magenta Biasina A. Magnetic resonance imaging and positron emission tomography in the diagnosis of neurodegenerative dementias. Funct Neurol. 2016;31(4):205-215. https://doi.org/10.11138/fneur/2016.31.4.205
Herholz K, Westwood C. Haense Evaluation of a calibrated (18)F—FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. J Nucl Med. 2011;52(8):1218-1226. https://doi.org/10.2967/jnumed.111.090902
Litvinenko IV, Emelin AYu, Lobzin VYu, et al. Neuroimaging techniques for diagnosing Alzheimer’s disease and cerebrovascular diseases with cognitive impairment. Neurology, Neuropsychiatry, Psychosomatics. 2019;11(3S):18-25. (In Russ.). https://doi.org/10.14412/2074-2711-2019-3S-18-25
Jack C, Bennett D, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;4:535-562. https://doi.org/10.1016/j.jalz.2018.02.018
Petersen R, Touchon J. Consensus on mild cognitive impairment: EADS—ADCS. Res Pract AD. 2005;10:38-46.
Hughes C, Berg L, Danziger W, et al. A new clinical scale for the staging of dementia. Brit J Psychiatry. 1982;140:566-572. https://doi.org/10.1192/bjp.140.6.566
Yakhno NN, Zakharov VV. Cognitive and emotional-affective disorders in dyscirculatory encephalopathy. Rus Med Zhurn. 2002;12:539-543. (In Russ.).
Levin OS, Chimagomedova ASh. Cognitive disorders in discirculatory encephalopathy. Psikhiatriya. 2018;(78):158-166. (In Russ.).
O`Brien JT, Erkinjuntii T, Reisberg B, et al. Vascular cognitive impairment. Lancet Neurol. 2003;2(2):89-98. https://doi.org/10.1016/s1474-4422(03)00305-3
Erkinjuntti T, Gauthier S. The concept of vascular cognitive impairment. Front Neurol Neurosci. 2009;24:79-85. https://doi.org/10.1159/000197886
Odinak MM, Emelin AYu, Lobzin VYu. Cognitive impairment in cerebrovascular pathology. SPb.: SpetsLit; 2022. (In Russ.).
Damulin IV. Cognitive disorders in cerebrovascular pathology. S.S. Korsakov Journal of Neurology and Psichiatry. 2009;109(1):70-75. (In Russ.).
O’Sullivan M, Jones D, Summers P, et al. Evidence for cortical «disconnection» as a mechanism of age-related cognitive decline. Neurology. 2001;57: 632-638. https://doi.org/10.1212/WNL.57.4.632
Chui HC. Subcortical ischemic vascular dementia. Neurol Clin. 2007;(3):717-740. https://doi.org/10.1016/j.ncl.2007.04.003
Gavrilova SI. Pharmacotherapy of Alzheimer’s disease. M.: Pulse; 2007. (In Russ.).
Emelin AYu, Lobzin VYu, Vorobyov SV. Cognitive disturbances: a guide for doctors. M. 2019. (In Russ.).
Dubois B, Feldman H, Jacova C, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS—ADRDA criteria. Lancet Neurol. 2007;8:734-746. https://doi.org/10.1016/S1474-4422(07)70178-3
O’Brien JT. Role of imaging techniques in the diagnosis of dementia. Br J Radiol. 2007;80(Spec. 2):71-87. https://doi.org/10.1259/bjr/33117326
Heiss WD, Zimmermann-Meinzingen S. PET imaging in the differential diagnosis of vascular dementia. J Neurol Sci. 2012;322:268-273. https://doi.org/10.1016/j.jns.2012.09.023
Heiss WD. The Additional Value of PET in the Assessment of Cerebral Small Vessel Disease. J Nucl Med. 2018;59(11):1660-1664. https://doi.org/10.2967/jnumed.118.214270
Kerrouche N, Herholz K, Mielke R, et al. 18FDG PET in vascular dementia: differentiation from Alzheimer’s disease using voxel-based multivariate analysis. J Cereb Blood Flow Metab. 2006;26:1213-1221. https://doi.org/10.1038/sj.jcbfm.9600296
Herholz K, Carter S, Jones M. Positron emission tomography imaging in dementia. Br J Radiol. 2007;80(2):160-167. https://doi.org/10.1259/bjr/97295129
Oldan JD, Jewells VL, Pieper B, et al. Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist. AJNR Am J Neuroradiol. 2021;42(6):998-1007. https://doi.org/10.3174/ajnr.A7079
Smailagic N, Lafortune L, Kelly S, et al. 18F-FDG PET for prediction of conversion to Alzheimer’s disease dementia in people with mild cognitive impairment: an updated systematic review of test accuracy. J Alzheimers Dis. 2018;64:1175-1194.
Mielke R, Heiss WD. Positron emission tomography for diagnosis of Alzheimer’s disease and vascular dementia. J Neural Transm Suppl. 1998;53:237-250. https://doi.org/10.1007/978-3-7091-6467-9_21